Literature DB >> 15039299

Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.

Bojan Lalovic1, Brian Phillips, Linda L Risler, William Howald, Danny D Shen.   

Abstract

Oxycodone undergoes N-demethylation to noroxycodone and O-demethylation to oxymorphone. The cytochrome P450 (P450) isoforms capable of mediating the oxidation of oxycodone to oxymorphone and noroxycodone were identified using a panel of recombinant human P450s. CYP3A4 and CYP3A5 displayed the highest activity for oxycodone N-demethylation; intrinsic clearance for CYP3A5 was slightly higher than that for CYP3A4. CYP2D6 had the highest activity for O-demethylation. Multienzyme, Michaelis-Menten kinetics were observed for both oxidative reactions in microsomes prepared from five human livers. Inhibition with ketoconazole showed that CYP3A is the high affinity enzyme for oxycodone N-demethylation; ketoconazole inhibited >90% of noroxycodone formation at low substrate concentrations. CYP3A-mediated noroxycodone formation exhibited a mean K(m) of 600 +/- 119 microM and a V(max) that ranged from 716 to 14523 pmol/mg/min. Contribution from the low affinity enzyme(s) did not exceed 8% of total intrinsic clearance for N-demethylation. Quinidine inhibition showed that CYP2D6 is the high affinity enzyme for O-demethylation with a mean K(m) of 130 +/- 33 microM and a V(max) that ranged from 89 to 356 pmol/mg/min. Activity of the low affinity enzyme(s) accounted for 10 to 26% of total intrinsic clearance for O-demethylation. On average, the total intrinsic clearance for noroxycodone formation was 8 times greater than that for oxymorphone formation across the five liver microsomal preparations (10.5 microl/min/mg versus 1.5 microl/min/mg). Experiments with human intestinal mucosal microsomes indicated lower N-demethylation activity (20-50%) compared with liver microsomes and negligible O-demethylation activity, which predict a minimal contribution of intestinal mucosa in the first-pass oxidative metabolism of oxycodone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039299     DOI: 10.1124/dmd.32.4.447

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  55 in total

1.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

Authors:  Andrew J McLachlan; Sally Bath; Vasi Naganathan; Sarah N Hilmer; David G Le Couteur; Stephen J Gibson; Fiona M Blyth
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

4.  Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Authors:  Anand K Deo; Bhagwat Prasad; Larissa Balogh; Yurong Lai; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2012-02-08       Impact factor: 3.922

Review 5.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 6.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

7.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

8.  Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy.

Authors:  Jacek Biesiada; Vidya Chidambaran; Michael Wagner; Xue Zhang; Lisa J Martin; Jaroslaw Meller; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.

Authors:  Hikaru Sato; Takafumi Naito; Takuya Ishida; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2016-08-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.